Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1985 1
1986 1
1987 2
1988 5
1989 1
1990 2
1991 1
1992 2
1993 7
1994 1
1995 1
1996 2
1998 3
1999 5
2000 7
2001 3
2002 5
2003 5
2004 11
2005 11
2006 18
2007 21
2008 23
2009 30
2010 27
2011 36
2012 43
2013 34
2014 40
2015 61
2016 63
2017 83
2018 84
2019 131
2020 112
2021 109
2022 109
2023 91
2024 72

Text availability

Article attribute

Article type

Publication date

Search Results

1,134 results

Results by year

Filters applied: . Clear all
Page 1
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Mai HQ, et al. Among authors: chen qy. JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181. JAMA. 2023. PMID: 38015220 Free PMC article. Clinical Trial.
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Liu Z, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Feng H, Yao S, Keegan P, Xu RH. Mai HQ, et al. Among authors: chen qy. Nat Med. 2021 Sep;27(9):1536-1543. doi: 10.1038/s41591-021-01444-0. Epub 2021 Aug 2. Nat Med. 2021. PMID: 34341578 Clinical Trial.
Metals and Mechanisms of Carcinogenesis.
Chen QY, DesMarais T, Costa M. Chen QY, et al. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:537-554. doi: 10.1146/annurev-pharmtox-010818-021031. Annu Rev Pharmacol Toxicol. 2019. PMID: 30625284 Free PMC article. Review.
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin DF, Liu LT, Luo DH, Li YF, Deng SW, Guo L, Zeng MS, Cai XY, Liu SL, Sun XS, Li XY, Li SC, Chen QY, Tang LQ, Mai HQ. Yuan L, et al. Among authors: chen qy. Nat Commun. 2023 Aug 14;14(1):4893. doi: 10.1038/s41467-023-40402-x. Nat Commun. 2023. PMID: 37580352 Free PMC article. Clinical Trial.
Arsenic: A Global Environmental Challenge.
Chen QY, Costa M. Chen QY, et al. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:47-63. doi: 10.1146/annurev-pharmtox-030220-013418. Annu Rev Pharmacol Toxicol. 2021. PMID: 33411580 Review.
FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression.
Wu J, Wen T, Marzio A, Song D, Chen S, Yang C, Zhao F, Zhang B, Zhao G, Ferri A, Cheng H, Ma J, Ren H, Chen QY, Yang Y, Qin S. Wu J, et al. Among authors: chen qy. Cell Death Dis. 2024 Apr 20;15(4):282. doi: 10.1038/s41419-024-06635-4. Cell Death Dis. 2024. PMID: 38643215 Free PMC article.
1,134 results